A
Alcista
Alcista · 25%PRGO
$33.09
Precio del escenario
$16.630
+0.151 (+0.91%)Al cierre
Loading chart…
- Máximo
- 16.680
- Apertura
- 16.540
- Precio medio ponderado por volumen
- 16.52
- Volumen
- 2.44M
- Capitalización
- —
- Mínimo
- 16.260
- Importe
- 40.31M
- EV/EBITDA, TTM
- 9.24
Perrigo Company plc is a pure-play self-care company. The Company provides health and wellness solutions. Its segments include Self Care, Specialty Care, and Infant Formula. Self Care comprises Upper Respiratory, Digestive Health, Pain & Sleep and Healthy Lifestyle product categories globally. Specialty Care comprises our Women's Health and Skin Health product categories globally. Infant Formula comprises the Infant Formula product category, which includes nutritional products designed to meet the dietary needs of infants. It provides a store-branded private label provider of self-care products in many categories, including upper respiratory, healthy lifestyle and women's health, along with brands including Opill and Mederma. Its Europe portfolio consists primarily of brands, including Compeed, ellaOne, Solpadeine, Jungle Formula, and ACO. Its upper respiratory products include Nasonex 24HR Energy, Mucus DM, All Day Allergy, Nighttime Cold & Flu, and Allergy Relief.
Análisis de IA of Perrigo Company PLC (PRGO)
ComprarPerrigo Company PLC is a good buy right now, trading at $16.63 with a forward P/E ratio of 5.97, suggesting it is undervalued compared to its earnings potential. Additionally, the stock has shown a strong 20-day change of +22.64%, indicating positive momentum. However, investors should be cautious due to a recent net income loss of $398.6 million in Q1 2026, which poses a risk to future profitability.
Recomendaciones de analistas (18)
+22.25% de potencial alcista
Mantener
6 Comprar
11 Mantener
1 Vender
Actual: 16.63
Mínimo
18.00
Promedio
20.33
Máximo
23.00
JPMorgan
Neutral
$15
2026-02-27
JPMorgan
2026-02-27
Precio objetivo
$15
Neutral
Canaccord
Comprar
$17
2026-02-27
Canaccord
2026-02-27
Precio objetivo
$17
Comprar
JPMorgan
Neutral
$18
2025-12-15
JPMorgan
2025-12-15
Precio objetivo
$18
Neutral
Canaccord
Comprar
$20
2025-11-06
Canaccord
2025-11-06
Precio objetivo
$20
Comprar
JPMorgan
Neutral
$20
2025-11-06
JPMorgan
2025-11-06
Precio objetivo
$20
Neutral
Métricas de valoración
El PER previsto actual de Perrigo Company PLC (PRGO) es 5.97, frente a su media de 5 años de 10.60.
Escenarios de precio de Alphio AI para PRGO
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con PRGO en cartera
Cronología de eventos
Noticias
6.009-28NASDAQ.COMPerrigo Shares Surpass Analyst Target Price of $15.25
1.008-27PRnewswirePerrigo to Participate in Barclays Global Consumer Conference
2.008-27NASDAQ.COMPerrigo Shares Surpass Analyst Target Price of $14.50
9.508-22NASDAQ.COMPerrigo Faces Financial Challenges Amid CEO Transition
5.008-22FoolPerrigo CEO Abruptly Departs Amid Weak Financial Performance
Preguntas frecuentes sobre PRGO, respondidas por Alphio AI
Perrigo Company plc is a pure-play self-care company. The Company provides health and wellness solutions. Its segments include Self Care, Specialty Care, and Infant Formula. Self Care comprises Upper Respiratory, Digestive Health, Pain & Sleep and Healthy Lifestyle product categories globally. Specialty Care comprises our Women's Health and Skin Health product categories globally. Infant Formula comprises the Infant Formula product category, which includes nutritional products designed to meet the dietary needs of infants. It provides a store-branded private label provider of self-care products in many categories, including upper respiratory, healthy lifestyle and women's health, along with brands including Opill and Mederma. Its Europe portfolio consists primarily of brands, including Compeed, ellaOne, Solpadeine, Jungle Formula, and ACO. Its upper respiratory products include Nasonex 24HR Energy, Mucus DM, All Day Allergy, Nighttime Cold & Flu, and Allergy Relief. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Perrigo Company PLC is a good buy right now, trading at $16.63 with a forward P/E ratio of 5.97, suggesting it is undervalued compared to its earnings potential. Additionally, the stock has shown a strong 20-day change of +22.64%, indicating positive momentum. However, investors should be cautious due to a recent net income loss of $398.6 million in Q1 2026, which poses a risk to future profitability.
18 analysts cover PRGO: 6 rate it Buy, 11 Hold and 1 Sell. The average price target is 20.33.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.